A large 23andMe-based GWAS found that common variants in GLP1R and GIPR help explain why some people lose more weight or experience more nausea and vomiting on GLP-1 drugs. The findings suggest ... Distinct GLP1R and GIPR variants correlated with nausea/vomiting risk, with a GIPR signal appearing tirzepatide-specific and showing markedly increased vomiting odds.

Understanding the Context

New studies from 23andMe suggest ...